Fibroblast growth factor 2-stimulated proliferation is lower in muscle precursor cells from old rats by NC DOCKS at Appalachian State University & Zwetsloot, Kevin
Archived version from NCDOCKS Institutional Repository http://libres.uncg.edu/ir/asu/ 
Fibroblast growth factor 2-stimulated proliferation is lower in 
muscle precursor cells from old rats
Authors
Seth S. Jump, Tom E. Childs, Kevin A. Zwetsloot, Frank W. Booth and Simon J. Lees
Abstract
In aged skeletal muscle, impairments in regrowth and regeneration may be explained by a 
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kinase (JNK) signalling was ruled out as an FGF2-stimulated proliferation pathway in MPCs. 
Inhibition of JNK had no effect on FGF2 signalling to BrdU incorporation, and FGF2 treatment 
was associated with increased phosphorylation of p38, which inhibits, rather than stimulates, 
BrdU incorporation in MPCs. Surprisingly, the commonly used vehicle, dimethyl sulphoxide, 
rescued proliferation in MPCs from old animals. These findings provide insight for the 
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In aged skeletal muscle, impairments in regrowth and regeneration may be explained by a 
decreased responsiveness of muscle precursor cells (MPCs) to environmental cues such as growth 
factors. We hypothesized that impaired responsiveness to fibroblast growth factor 2 (FGF2) in 
MPCs from old animals would be explained by impaired FGF2 signalling. We determined that 
5-bromo-2f-deoxyuridine (BrdU) incorporation and cell number increase less in MPCs from 
32- compared with 3-month-old rats. In the presence of FGF2, we demonstrated that there were 
age-associated differential expression patterns for FGF receptor 1 and 2 mRNAs. Measurement 
of downstream signalling revealed that that mitogen-activated protein kinase/ERK kinase 1/2 
(MEK1/2)–extracellular signal-regulated kinase 1/2, protein kinase C and p38 were FGF2-driven 
pathways in MPCs. Uniquely, protein kinase C signalling was shown to play the largest role in 
FGF2-stimulated proliferation in MPCs. c-Jun N-terminal kinase (JNK) signalling was ruled 
out as an FGF2-stimulated proliferation pathway in MPCs. Inhibition of JNK had no effect 
on FGF2 signalling to BrdU incorporation, and FGF2 treatment was associated with increased 
phosphorylation of p38, which inhibits, rather than stimulates, BrdU incorporation in MPCs. 
Surprisingly, the commonly used vehicle, dimethyl sulphoxide, rescued proliferation in MPCs 
from old animals. These findings provide insight for the development of effective treatment 
strategies that target the age-related impairments of MPC proliferation in old skeletal muscle. 
Muscle precursor cells (MPCs), or satellite cells, are adult 
skeletal muscle stem cells that are located between the 
basal lamina and the plasmalemma (Mauro, 1961; Schultz 
& McCormick, 1994). They reside in a quiescent state and, 
when activated, MPCs undergo proliferation, migration 
and subsequent differentiation, whereby they fuse and 
contribute new myonuclei (Hawke & Garry, 2001; Roy 
et al. 1999). Proliferation of MPCs is required for the 
effective regrowth and regeneration of skeletal muscle 
(Wheldon et al. 1982). Importantly, both regrowth and 
regeneration are impaired in aged skeletal muscle (Brooks 
& Faulkner, 1990; Pattison et al. 2003), largely due to a 
decreased activation of MPCs (Carlson et al. 2008). One 
potential contributor to attenuated MPC proliferation in 
aged skeletal muscle could be a blunted responsiveness 
to proliferation-stimulating growth factors in skeletal 
muscle. 
There are multiple growth  factors  associated  with 
the local skeletal muscle milieu which stimulate the 
proliferation of MPCs (Gopinath & Rando, 2008). 
Fibroblast growth factor 2 (FGF2), previously known as 
basic FGF or bFGF, is a polypeptide growth factor that 
stimulates MPC proliferation (Allen & Boxhorn, 1989; 
Mezzogiorno et al. 1993). Fibroblast growth factor 2 
binds to low-affinity (heparan sulphate proteoglycan, 
HSPG) and high-affinity receptors (FGFR), the latter 
having four isoforms. After FGF2 binds to its receptor, 
FGFR dimers are trans-phosphorylated, and downstream 
signalling is initiated to stimulate proliferation (Plotnikov 
et al. 1999; Ornitz & Itoh, 2001; Chen &  Forough, 
2006). Within muscle precursor cells, FGF2 is known to 
stimulate mitogen-activated protein kinase/ERK kinase 
1/2 (MEK1/2)–extracellular signal-regulated kinase 1/2 
(ERK1/2)  signalling  (Campbell  et  al.  1995;  Kastner 
 
 
 
et al. 2000; McFarland & Pesall,  2008),  which  in 
turn stimulates proliferation. Other evidence has shown 
that FGF2 treatment activates signal transduction and 
activation of transcription (STAT) or c-Jun N-terminal 
kinase (JNK) signalling (Megeney et al. 1996). However, 
the role of additional mitogen-activated protein kinase 
(MAPK) pathways in FGF2-stimulated proliferation, to 
our knowledge, has not been fully elucidated in MPCs. 
The functionally associated outcome of increased FGF2 
stimulation is muscle growth. In skeletal muscle, FGF2 
is expressed at a high level during muscle regeneration 
(Anderson et al. 1995), and FGF2 injection has been 
shown to improve recovery in reinnervated (Iwata et al. 
2006) and dystrophic muscle (Lefaucheur & Sebille, 
1995a). Neutralizing antibodies to FGF2 attenuate skeletal 
muscle repair (Lefaucheur & Sebille, 1995b). Upon muscle 
damage, FGF2 is released from the extracellular matrix, 
macrophages and fibroblasts, which infiltrate into the 
muscle as part of the repair process. Anatomically, MPCs 
exist in close proximity to the capillaries, which are also 
likely to serve as a source of FGF2 via production from the 
endothelial cells and the circulation. 
The present study was performed to complete two 
objectives. The first objective was to determine the effect 
of FGF2 stimulation on MPC proliferation from 3- 
(young) and 32-month-old (aged) animals by assessing 
the proportion of cells in S phase in MPC cell culture 
using flow cytometric analysis separation of 5-bromo-21- 
deoxyuridine (BrdU) pulse-labelled MPCs and increases 
in cell number. The second objective was to determine 
the FGF2-dependent signalling pathways in MPCs from 
young and aged animals and assess whether ageing 
differences in signalling to BrdU incorporation exist. 
 
Methods 
Animals 
All animal procedures were approved by the Animal 
Care and Use Committee at the University of Missouri- 
Columbia. Young (3-month-old) and old (32-month-old) 
Fischer 344 × Brown Norway F1 hybrid rats were obtained 
from the National Institute of Aging (NIA). Animals were 
housed with a 12 h–12 h light–dark cycle at 21◦C and were 
provided with food and water ad libitum. At the time 
of cell isolation, animals were deeply anaesthetized with 
an intraperitoneal injection of ketamine (80 mg kg−1), 
xylazine (10 mg kg−1) and acepromazine (4 mg kg−1), 
and killed by exsanguination. Following exsanguination, 
gastrocnemius and plantaris muscles were dissected. 
 
Isolation of muscle precursor cells 
Muscle precursor cells were isolated using the method 
developed by Allen et al. (1997), incorporating the 
modifications made by Lees et al. (2006). Cells were 
isolated from gastrocnemius and plantaris muscles and 
transferred to a 150 mm tissue culture-treated plate 
(negative charge induced) for a 24 h preplate incubation. 
After 24 h, MPCs were transferred  to  Matrigel-coated 
(BD Biosciences, San Jose, CA,  USA)  150 mm  plates 
(0.1 mg ml−1 Matrigel, 60 min at 37◦C) and cultured for 
3–5 days in growth medium (GM, composed  of  20% 
fetal bovine serum, 100 units ml−1  penicillin, 100 μg ml−1 
streptomycin and 40 μg ml−1 gentamicin in  Ham’s  F- 
10).  This  method  has  been  shown  previously  to  yield 
a population of cells with a high degree  of  myogenic 
purity (Lees et al. 2006). The MPCs  were  passaged 
once to Matrigel-coated cell culture plates for further 
experimentation at passage 1 unless indicated otherwise. 
The MPCs were cultured in a humidified incubator with 
ambient air and 5% CO2  at 37◦C. 
 
Cell proliferation 
Muscle precursor  cells  were  passaged  to  100 mm 
plates (150 000 cells  per  plate)  and  grown  for  24 h 
in GM. After 24 h, medium was changed to low- 
mitogen/serum medium [2% horse serum  (HS)  with 
100 nM dexamethasone], and the MPCs  were  treated 
with FGF2 or vehicle. Medium was changed to low- 
mitogen/serum medium in order to test the specific 
effects of FGF2 on MPC proliferation by minimizing the 
influence of other mitogens. 
At 23 h of treatment with FGF2, MPCs were pulse- 
labelled with BrdU (10 μM) for 1 h at 37◦C in the 
humidified incubator. After 1 h, MPCs were trypsinized, 
fixed with ice-cold 70%  EtOH, and stored at  4◦C 
until further analysis. Immunodetection of BrdU using 
flow cytometry was performed as described by Lees 
et al. (2008). Briefly, cells were incubated in 2 N HCl 
for 30 min, followed by two neutralizing washes with 
0.1 M sodium borate (pH 8.5) and a  final wash in 
Dulbecco’s-phosphate-buffered saline (PBS). Cells were 
incubated with anti-BrdU–fluoroscein (5 μg ml−1 in 0.1% 
bovine serum albumin in PBS, Roche Applied Sciences, 
Indianapolis, IN, USA) for 30 min. Twenty thousand cells 
were analysed using a BD FAC-Scan and CellQuest Pro 
software (BD Biosciences), and the proportions of BrdU- 
positive (BrdU+) and and BrdU-negative (BrdU−) nuclei 
were determined as described previously (Lees et al. 2008). 
 
Cell number 
Muscle precursor cells were seeded onto to six-well plates 
(12 500 cells per well) and grown for 24 h in GM. After 
24 h, the medium was changed to low-mitogen medium 
and the MPCs were treated with variable doses of FGF2 for 
48 h; the medium was refreshed after 24 h. The MPCs were 
harvested from the six-well culture plates, and cell number 
was determined by measuring cells adherent to the cell 
 
 
 
Table 1. Forward and reverse primers for the FGF receptors 
 
 
Receptor type Forward primer Reverse primer 
 
FGFR1 5
1
-CAGGGCTACCAGCCAACAA-3
1
 5
1
-CACTGTACACCTTGCACATGAACTC-3
1
 
FGFR2 5
1
-GTGATGCCCAGCCCCATA-3
1
 5
1
-AGCCCATCAGGTCCATATTTACTG-3
1
 
FGFR3 5
1
-CAGAAGCTATTGGCATCGACAAG-3
1
 5
1
-TCGCATCATCTTTCAGCATCTT-3
1
 
FGFR4 5
1
-TCCCGGCCAGACCAAAC-3
1
 5
1
-TCAGGTCTGCCAAATCCTTGT-3
1
 
 
culture plate using the CyQUANT assay kit (Invitrogen, 
Carlsbad, CA, USA). 
 
Real-time PCR 
Muscle precursor cells were passaged to 60 mm plates 
(55 000 cells per plate) and grown for 24 h in GM. 
After 24 h, the medium was changed to low-mitogen 
medium and the MPCs were treated with one dose of 
FGF2 (10 ng ml−1) for a 24 h treatment. The RNA was 
harvested from the cell culture plate using RLT lysis buffer 
(Qiagen, Valencia, CA, USA) with 1% β-mercaptoethanol 
and passed through a QIAshredder (Qiagen). The RNA 
was isolated and purified using RNeasy micro kitOR 
(Qiagen),  and  reverse  transcription  was  performed. 
Quantification of RNA was done using spectrophotometry 
by measuring the absorbance at 260 nm, and purity 
was determined by the ratio of absorbance at 260 and 
280 nm. Verification of RNA integrity was determined 
by agarose gel electrophoresis and ethidium bromide 
staining. Levels of FGFR(1–4) mRNA were determined 
using real-time quantitative PCR using SYBR green PCR 
Master Mix (Applied Biosystems, Foster City, CA, USA) 
and an ABI Prism 7000 (Applied Biosystems) using 25 ng 
cDNA. Primers for each FGF receptor are shown in Table 1. 
Data were analysed using the Ct method. Primers for 18S 
rRNA were obtained from Applied Biosystems. 
Standard curves for target mRNA and 18S rRNA were run 
in order to determine amplification efficiency. Each FGF 
receptor value was normalized to values for 18S ribosomal 
RNA from control samples. Each FGFR(1–4) mRNA level 
was determined in mitogen-rich (without FGF2) and in 
low-mitogen conditions with FGF2 stimulation in MPCs 
from 3- and 32-month-old animals. 
 
Western blot 
Muscle precursor cells were seeded on 100 mm plates 
(150 000 cells per plate) and grown for 24 h in GM. After 
48 h, the medium was changed to low-mitogen medium 
for 3 h. Then, the MPCs were treated with FGF2 (0, 
0.5 or 10 ng ml−1) for 10 min. After 10 min treatment, 
radio-immunoprecipitation assay (RIPA) buffer (50 mM 
Tris pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% sodium 
deoxycholate and 0.1% SDS) was used to lyse and harvest 
cells. Protein concentration was determined using DC 
Assay (BioRad, Hercules, CA, USA). Equal amounts 
of protein were loaded and separated via SDS-PAGE, 
and protein was transferred to nitrocellulose membranes 
(Fischer-Scientific, Pittsburgh, PA, USA). To ensure equal 
loading, nitrocellulose membranes were stained with 
Ponceau S (Sigma-Aldrich, St. Louis, MO, USA), which 
allows for both the qualitative visualization and the 
quantification of the amount of protein in a given lane 
(Klein et al. 1995). Antibodies for phospho-MEK1/2 
(Ser217/221), phospho-ERK1/2 (Thr202, Tyr204), and 
phospho-p38 (Thr180/Tyr182) were obtained from Cell 
Signaling Technology (Beverly, MA, USA). Anti-rabbit 
immunoglobulin G and anti-mouse immunoglobulin G 
secondary antibodies conjugated with horseradish 
peroxidase were obtained from Pierce Biotechnology 
(Rockford, IL, USA). Primary–secondary immuno- 
complexes were visualized using a chemiluminescent 
reaction mixture, and images were scanned. The signal 
bands were scanned using a Kodak Image Station 
4000R Digital Imaging System (Eastman Kodak Company, 
Rochester, NY, USA) and quantified using Kodak 
molecular imaging software (version 4.0). 
 
 
Pathway inhibitors 
Muscle precursor cells were passaged to 100 mm plates 
(150 000 cells per plate) and grown for 24 h in GM. After 
24 h, the medium was changed to low-mitogen medium 
and chemical inhibitors were added. Inhibition of MEK1/2 
was performed in MPCs treated with FGF2 using two 
chemical inhibitors: the more specific MEK1/2 inhibitor 
U0126 (10 μM, Cell Signaling Technology) and the non- 
specific MEK1/2 inhibitor SL327 (40 μM, Calbiochem, 
Gibbstown, NJ, USA). Previously, non-specific effects of 
the non-specific MEK1/2 inhibitor have been documented 
(Scherle et al. 2000). 
A Western blot dose–response experiment was 
performed using both MEK1/2 inhibitors to determine 
the effective dose of inhibition. The p38 inhibitor, 
SB203580 (10 μM, Calbiochem), the protein kinase C 
(PKC) inhibitor, bisindolylmaleimide I (BIS I, 10 μM, 
Calbiochem), and the JNK inhibitor, SP600125 (10 μM, 
Calbiochem), were used to determine the contribution 
of p38, PKC and JNK pathways, respectively, in FGF2- 
dependent signalling. Optimal doses for  SB203580, 
BIS I and SP600125 were obtained from the literature 
(Kefaloyianni et  al.  2006; Huang et  al.  2007; Krejci 
et al. 2007). After a 1 h treatment with inhibitors, MPCs 
were  treated  with  FGF2  (10 ng ml−1)  for  24 h.  After 
 
 
 
23 h of treatment, the MPCs were pulse-labelled  with 
BrdU (10 μM) for 1 h and harvested as described above 
(see ‘Cell proliferation’). For Western blot measurements, 
inhibitors were added to low-mitogen medium 1 h prior 
to treatment.  The FGF2 was  added to the  medium for 
10 min, followed by cell lysis (RIPA buffer). 
 
 
Statistics 
Muscle precursor cells isolated from one animal were 
considered  an  n value  of  1.  Data  are  presented  as 
 
 
Figure 1. Fibroblast growth factor 2-stimulated MPC 
proliferation 
A, CyQUANT assay for cell number in MPCs from 3- and 
32-month-old animals. The assay was performed after 48 h of FGF2 
treatment (n = 4). The cell number at each dose of FGF2 stimulation 
was normalized to control cell number (CON; 0 ng ml
−1 
FGF2). 
B, BrdU incorporation data of MPCs from 3- and 32-month-old 
animals treated with different doses of FGF2 for 24 h (n = 4 for 1.0, 
2.5 and 10 ng ml
−1
, n = 6 for 5 ng ml−1 and n = 2 for 100 ng ml−1). 
Values are means ± S.E.M. ∗ Significant difference for cell number 
compared with 32-month-old animals (P < 0.05). 
means ± S.E.M. Comparisons between groups were made 
using ANOVA (SigmaStat, version 3.1, Systat Software, 
San Jose, CA, USA). Statistical significance was accepted 
at P < 0.05. 
 
Results 
In aged skeletal muscle, impairment of MPC proliferation 
is likely to contribute to  decrements  in  regrowth 
and regeneration (Conboy et al. 2003; Carlson et al. 
2008). Since FGF2 is a potent stimulator of MPC 
proliferation, the hypothesis was tested that FGF2- 
stimulated proliferation was attenuated in MPCs isolated 
from aged animals compared with young animals. In 
order to determine the mitogenic effects on FGF2 on 
MPCs isolated from young and old animals, dose–
response curves for FGF2-stimulated proliferation in 
low-mitogen culture conditions (2% HS) were obtained. 
In response to multiple doses of FGF2, MPCs from 
32-month-old animals exhibited a lower number of cell 
(Fig. 1A) and reduced BrdU incorporation (Fig. 1B) 
compared with MPCs from 3-month-old animals. 
We were interested in demonstrating that FGFR mRNAs 
are responsive to the removal of mitogens in GM and to 
the FGF2 concentration in the medium, and that the age- 
dependent decrease in FGF2-stimulated proliferation may 
be explained by differences in FGFR expression (Fig. 2A). 
Expressions of mRNA for the four FGFR isoforms in 
MPCs from 3- and 32-month-old animals were first 
determined in mitogen-rich GM, and no age differences 
were found (Fig. 2A). The relative expression levels of 
the FGFR isoform mRNAs were found to be present in 
the rank order of FGFR4 » FGFR1 = FGFR2 = FGFR3. 
Replacment of the mitogen-rich GM medium with low- 
serum medium resulted in a decrease in mRNA content of 
all of the FGF2Rs (Fig. 2A). 
Next, FGFR isoform mRNA expression was measured 
in the presence of FGF2 in the 2% HS (low-mitogen) 
culture conditions to minimize the effect of other mitogens 
found in high-mitogen serum. The mRNA for each FGFR 
isoform decreased in the presence of FGF2, compared 
to high-serum, demonstrating receptor downregulation 
(Fig. 2B). However, the mRNA for FGFR1 decreased more 
in MPCs from 32-month-old animals, while the mRNA 
for FGFR2 decreased more in MPCs from 3-month-old 
animals. There were no age differences in FGFR3 and 
FGFR4 mRNAs. 
Since age differences did exist in both proliferation and 
the mRNA levels of FGFR1 and FGFR2 in the presence 
of FGF2 in low-mitogen medium (2% HS), downstream 
proliferation-specific signalling was measured. Figure 3A 
demonstrates that 10 ng ml−1 FGF2 caused a nearly 400% 
increase in the phosphorylation of MEK1/2 in MPCs 
from young and aged animals without any difference 
between the ages. An approximately 50 and 140% increase 
 
 
 
in ERK1/2 phosphorylation occurred in response to 0.5 
and 10 ng ml−1 FGF2, respectively (Fig. 3B), again with 
no difference between the ages. 
Fibroblast growth factor 2 is known to increase p38 
activation (Lee et al. 2002; Matsumoto et al. 2002; Khalil 
et al. 2005). Further, it has been reported that inhibition of 
p38 MAPK induces cell proliferation of H9c2 rat cardiac 
myoblasts in differentiation medium and that mice lacking 
p38α exhibit increased myoblast proliferation (Lee et al. 
2002; Perdiguero et al. 2007). Therefore, p38 signalling in 
response to FGF2 stimulation was tested next. In response 
to FGF2, there was an approximately 80% increase in the 
phosphorylation of p38 protein in MPCs from 3- and 
32-month-old animals, with no age difference observed 
(Fig. 4). Thus, Figs 3 and 4 indicate that MEK1/2–ERK1/2 
and p38 signalling are both FGF2-responsive pathways for 
MPC proliferation. 
In order to expand the investigation of FGF2- 
induced signalling and BrdU incorporation in MPCs, 
MEK1/2–ERK1/2, p38, JNK and PKC pathway inhibitors 
were next used. By inhibiting the signalling pathway, 
we would theoretically be able to test whether age-
dependent differences exist downstream of the 
phosphorylation of ERK1/2 and p38. However, 
preliminary experiments using these inhibitors revealed 
that the age-associated phenotype in FGF2-dependent 
proliferation was eliminated. The commonly used vehicle, 
DMSO, was used in each pathway inhibition experiment; 
we therefore remarkably found that the addition of DMSO 
in the presence of FGF2 rescued the impaired proliferation 
in MPCs isolated from 32-month-old animals (Fig. 5). 
Based on the finding  that  MPCs  from  32-month- 
old animals differentially increased their proliferation 
response in the presence  of  the  vehicle  (DMSO)  for 
the pathway inhibitors, ageing differences could not be 
tested, and remaining experiments were performed on 
MPCs isolated from young animals only. Figure 6A and 
B demonstrates inhibition of FGF2-stimulated ERK1/2 
phosphorylation in the presence of both MEK1/2– ERK1/2 
inhibitors, U0126 and the non-specific MEK1/2 inhibitor. 
Based on these experiments, the doses which corresponded 
to a 100% inhibition of FGF2-stimulated phosphorylation 
were used for proliferation experiments. In the presence 
of U0126, FGF2-stimulated BrdU incorporation was 
reduced by ∼20%, but remained greatly elevated above 
untreated control cultures (Fig. 6C). In the presence of 
the non-specific MEK1/2 inhibitor, the FGF2-stimulated 
incorporation of BrdU was reduced to values similar to 
those without FGF2 (control). However, the non-specific 
MEK1/2 inhibitor is not considered to be as specific as 
U0126 and has been shown to inhibit PKC in addition 
to MEK1/2–ERK1/2 signalling (Scherle et al. 2000). To 
test the potential role of PKC in FGF2-stimulated BrdU 
incorporation, the PKC inhibitor, bisindolylmaleimide I 
(BIS I), was next used. Inhibition of PKC reduced the 
FGF2-stimulated BrdU incorporation by ∼40% (Fig. 6C). 
Therefore, the two inhibitors, U0126 and BIS I, were 
used together. The combined use of U0126 and BIS I did 
not reduce the FGF2-stimulated BrdU incorporation any 
further than BIS I alone (Fig. 6C). These data suggest that 
∼60% of the FGF2-stimulated BrdU incorporation is a 
result of an additional signalling pathway. Since others 
have suggested that p38 or JNK signalling are activated 
by FGF2 (Megeney et al. 1996), p38 and JNK were next 
examined. 
 
 
Figure 2. Quantification of mRNA for FGFR isoforms 
A, mRNA for FGFRs determined in MPCs from 3- and 32-month-old 
animals after 24 h in GM (n = 4 for young and old). Relative quantities 
for each isoform were determined based on the relative quantity value 
for FGFR1 from 3-month-old animals set to 1. B, quantification of 
mRNA in MPCs from 3- and 32-month-old animals after 24 h of FGF2 
treatment (n = 3 for young and old). Relative quantities for each 
isoform were determined based on the relative quantity of FGFR1 from 
3-month-old animals in GM set to 1. All relative quantities of FGFR1–4 
mRNAs in low-serum conditions were significantly less than their 
respective high-serum values. The relative expression levels of the  
FGFR isoform mRNAs were significantly different in the rank order of 
FGFR4 » FGFR1 = FGFR2 = FGFR3. Different letters denotes a 
significant difference between groups. 
 
 
 
 
 
Figure 3. Cell signalling measured by Western blot 
A, Western blot analysis of the increase in phosphorylated MEK1/2 (Ser217/Ser221) in MPC cell lysates with FGF2 
treatment (0, 0.5 or 10 ng ml
−1
) with a representative Western blot; n = 8 for young and n = 7 for old. Muscle 
precursor cells were grown for 48 h in GM. Then, the medium was changed to low-serum medium for 3 h. After 
3 h, the MPCs were treated with FGF2 for 10 min. B, Western blot analysis of the increase in phosphorylated 
ERK1/2 (Thr202/Tyr204) in MPC cell lysates with FGF2 treatment (0, 0.5 or 10 ng ml
−1
) with a representative 
Western blot; n = 9 for young and n = 8 for old. Cell culture conditions were same as in A. Different letters 
denote a significant difference between FGF2 doses (P < 0.05). 
 
 
Figure 4. Representative Western blot showing levels of 
phosphorylated p38 protein (Thr180/Tyr182) in MPC cell lysates 
The figure shows quantitative Western blot data (n = 6 for young and 
old) from MPCs treated with FGF2 (0 or 10 ng ml
−1
). Muscle precursor 
cells were grown in GM for 24 h. After 24 h, GM was changed to 
low-serum medium for a 3 h equilibration period. After 3 h of 
treatment, FGF2 was added to the medium for a 10 min treatment. 
Data were analysed by two-way ANOVA. Different letters denote 
statistical significance (P < 0.05). 
 
Inhibition of JNK had no effect on FGF2 signalling 
to BrdU incorporation (data not shown), whereas p38 
inhibition (10 μM SB203580) in the presence of FGF2 
resulted in an approximately 30% increase in BrdU 
incorporation compared with FGF2-treated MPCs with 
 
 
Figure 5. Bromodeoxyuridine-positive nuclei with MEK1/2 and 
PKC inhibition in the presence of FGF2 (10 ng ml−1) and without 
or with DMSO (0.1%) 
Muscle precursor cells were grown for 24 h in GM. After 24 h, the 
medium was changed to low-serum medium with or without DMSO 
(n = 4 without DMSO and n = 6 with DMSO). After 1 h of exposure 
to DMSO, FGF2 (10 ng ml
−1
) was added to the medium. At 23 h of 
treatment with FGF2, MPCs were pulse-labelled with BrdU for 1 h. 
Muscle precursor cells were harvested and fixed after 24 h of 
treatment. Dissimilar letters denote significant differences between 
young and old without DMSO (P < 0.05). 
 
 
 
 
 
Figure 6.  MEK1/2 inhibitor Western blot and proliferation data 
A, representative Western blot for phosphorylated ERK1/2 (Thr202/Tyr204) in MPC cell lysates treated with FGF2 
(10 ng ml
−1
) in the presence or absence of U0126. Muscle precursor cells were grown for 24 h in GM. After 
24 h, the medium was changed to 2% HS, and chemical inhibitors were added to the medium (0.4% DMSO) 
1 h prior to a 10 min FGF2 treatment. B, representative Western blot for phosphorylated ERK1/2 (Thr202/Tyr204) 
in MPC cell lysates treated with FGF2 (10 ng ml
−1
) the presence of MEK1/2 inhibitor SL327 with the same cell 
culture conditions as in A. C, BrdU-positive nuclei with MEK1/2 and PKC inhibition in the presence of FGF2; 
n = 6 for young and old. CON = no FGF2 + DMSO (0.1%). Passage 2 MPCs were grown for 24 h in GM. After 
24 h, the medium was changed to low-serum medium, and MEK1/2 inhibitors (10 μM U0126 and 40 μM MEK1/2 
inhibitor) and PKC inhibitior (10 μM bisindolylmaleimide I) were added for 1 h, prior to treatment with FGF2 for 
23 h. Different letters denote significant differences between inhibitor types or conditions (P < 0.05). 
 
no inhibitor (Fig. 7). The addition of U0126 together with 
SB203580 resulted in proliferation values that were 20% 
higher than U0126 alone (Figs 6C and 7). These findings 
suggest that p38 and MEK1/2–ERK1/2 signalling could be 
modulated independently in FGF2-stimulated MPCs. 
 
 
Discussion 
Several significant and important findings are presented. 
In response  to increasing  doses of  FGF2,  cell 
number and BrdU incorporation increased less in 
single-passaged MPCs from 32-month-old animals 
compared with 3-month-old animals. However, in the 
presence of FGF2 in low-mitogen medium, ageing 
differences in the downregulation of mRNA levels for 
FGFR1 and FGFR2 were revealed. Signalling via MEK1/2– 
ERK1/2 was confirmed as a mechanism of FGF2 signalling 
to increase BrdU incorporation. Importantly, though, 
new observations of PKC signalling pathways to assist 
FGF2 signalling of BrdU incorporation in MPCs were 
documented. Further, inhibition of JNK had no effect on 
FGF2 signalling to BrdU incorporation and FGF2-induced 
phosphorylation of p38 inhibited BrdU incorporation 
in MPCs. To our knowledge, this is the first report to 
 
 
 
 
 
 
 
 
Figure 7. Bromodeoxyuridine-positive nuclei with MEK1/2 and 
p38 pathway inhibition in the presence of FGF2 (10 ng ml−1) 
CON = No FGF2 + DMSO (0.4%). Passage 2 MPCs were grown for 24 
h in GM. After 24 h, the medium was changed to low-serum   
medium containing 0.4% DMSO and with two different chemical 
inhibitors alone and in combination (10 μM U0126 and 10 μM 
SB203580). After 1 h of treatment with inhibitors, FGF2 was added to 
the media. After 23 h of treatment with FGF2, MPCs were 
pulse-labelled with BrdU (10 μM) for 1 h. Muscle precursor cells were 
harvested and fixed after 24 h of treatment. Different letters denote 
significant differences between inhibitor types or conditions 
(P < 0.05). n = 3 for no inhibitor, n = 6 for U0126, n = 2 for 
SB203580 + U0126 and CON and n = 4 for SB20580. 
 
 
 
demonstrate this relationship between FGF2, p38, PKC 
and proliferation in MPCs. Lastly, we have determined that 
the addition of DMSO to our culture media restored FGF2- 
stimulated BrdU incorporation values in MPCs from old 
animals to those of young animals. 
The combined inhibition of MEK1/2–ERK1/2 and PKC 
signalling did not reduce FGF2-stimulated proliferation 
any more than PKC inhibition alone. These data imply 
that another signalling pathway(s) must facilitate FGF2- 
stimulated proliferation. In support of this observation, 
the non-specific MEK1/2 inhibitor totally prevented 
FGF2-stimulated proliferation. Putatively, this was the 
result of the non-specific MEK1/2 inhibitor acting on 
multiple other signalling pathways. The lack of an ageing 
difference in phosphorylation of MEK1/2–ERK1/2 or p38 
suggests that these pathways probably do not explain the 
ageing impairment of FGF2-stimulated proliferation of 
MPCs. 
The intended use of pathway inhibitors was to dissect 
the relative contribution of various signalling pathways 
in the age-dependent decrease in FGF2-stimulated 
proliferation; however, DMSO itself rescued impaired 
proliferation in MPCs isolated from old animals. Dimethyl 
sulphoxide is the most commonly used organic solvent in 
cell culture experiments in which intracellular signalling 
inhibitors are used. It has been studied extensively, and 
numerous articles have been published about its chemical, 
biological and medical properties (Jacob & Herschler, 
1986; Yu & Quinn, 1994; Santos et al. 2003; Brien et al. 
2008). Dimethyl sulphoxide is known to have numerous 
biological properties; however, one property which could 
provide a potential explanation for the findings described 
here is its ability to act as a free radical scavenger. It 
is possible that the antioxidant effects of DMSO may 
provide protection to MPCs from 32-month-old animals 
and improve proliferation. 
The mRNA for each FGFR isoform decreased in 
the presence of low-serum, demonstrating receptor 
downregulation (Fig. 2B), and an interesting expression 
shift was observed when the cells were switched to FGF2- 
stimulated cells in low-mitogen medium. The FGFR1 
mRNA was suppressed less in low-mitogen medium, 
while FGFR2 mRNA was suppressed more in MPCs 
isolated from young animals after 24 h of FGF2 stimulation 
compared with suppression in MPCs from old animals. 
The physiological significance of FGFR1 and FGFR2 
isoform switching was not pursued owing to the lack of 
specific receptor inhibitors or antibodies to verify receptor 
knockdown. Since the signalling and biological responses, 
including mitogenic potential, elicited by different FGFRs 
differ substantially (Wang et al. 1994), it is possible that 
in MPCs from old animals, different outcomes of BrdU 
incorporation could occur. 
The redundancy of  signalling  pathways  employed 
by FGF2 could imply that FGF2 evolved as a critical 
regulator of MPC proliferation. Fibroblast growth factor 2 
can transduce downstream signalling through binding 
to the FGFR, a tyrosine kinase which activates both 
PKC and growth factor receptor-bound protein-son-of- 
sevenless (Grb–SOS) signalling that, in turn, activates 
Ras–Raf–MEK1/2 (Simons, 2004). Moreover, FGF2 is 
known also to bind to low-affinity heparan sulphate 
proteoglycans (HSPG) at the cell surface (Simons, 2004) 
in addition to the aforementioned high-affinity (FGFR) 
isoforms. One such example is that FGF2 can activate 
downstream signalling through syndecan-4, a type of 
HSPG, which activates PKC through its  interaction 
with phosphatidylinositol 4,5-biphosphate (Horowitz & 
Simons, 1998). Therefore, FGF2 activation of PKC 
results in downstream signalling that is dependent (Ras– 
Raf) and independent (syndecan-4) of MEK1/2. Our 
BrdU incorporation data suggest that FGF2-stimulated 
proliferation acts partly through PKC. However, since an 
additive effect was not observed by combining MEK1/2– 
ERK1/2 inhibition with PKC inhibition, it is possible that 
FGF2 stimulation of PKC in the current conditions is 
dependent on Ras–Raf activation. 
In MPCs, FGF2 stimulation of p38 was associated with 
an inhibition of BrdU incorporation. These findings may 
be explained by previous literature showing that its four 
isoforms (α, β, γ  and δ) exhibit variable or unknown 
effects on proliferation (Perdiguero et al. 2007). The p38 
inhibitor that was used in our study is known to be a highly 
specific inhibitor of p38α and p38β. These isoforms may 
act as negative regulators of proliferation in the presence 
of FGF2, while γ and δ may have no role or may potentiate 
proliferation. 
Previous literature investigating the response of skeletal 
muscle cells to FGF2 treatment has been equivocal. 
Johnson & Allen (1993) have demonstrated that cells from 
young rats (3–4 weeks old) responded to FGF2 at 18 h 
postplating, while cells from adult rats (9–12 months old) 
responded 48 h after plating. In addition, Mezzogiorno 
et al. (1993) reported a reduced mitogenic response in 
MPCs isolated from 22-month-old mice. In contrast, 
experiments using the single myofibre culture model 
showed no differences in FGF2-stimulated proliferation 
in growing (3-week-old), young adult (8- to 10-week-old) 
and old (9- to 11-month-old) rats (Yablonka-Reuveni et al. 
1999). Importantly, in the study of Yablonka-Reuveni et al. 
(1999), 9- to 11-month-old animals were designated as 
old, but this age group is probably better described as adult 
in terms of sarcopenia research. Furthermore, Shefer et al. 
(2006) demonstrated that in single-fibre cultures, isolated 
from fast-twitch mouse flexor digitorum brevis muscle, 
there was no difference in FGF2-stimulated proliferation. 
However, in these experiments, cells that did not stain 
positive for ERK1/2 (used as a marker for satellite cells) 
were excluded from the analyses and it was stated that more 
cells were excluded from the analyses from muscle fibre 
 
 
 
cultures of old mice. Therefore, our present findings are 
important because they demonstrate that MPCs isolated 
from sarcopenic animals exhibit a decreased proliferative 
response to FGF2 at all doses tested. Notably, the purity 
of the MPC culture used in the present study has been 
verified (Lees et al. 2006) using myogenic markers, and 
cell culture duration did not exceed 1 week after isolation 
from the animal. 
In this report, our data demonstrate the novel 
finding that there are age-associated impairments of 
FGF2-stimulated BrdU incorporation in MPCs from 32-
month-old animals. Also, an ageing-associated 
difference exists  in  the mRNA  expression  of FGFR1 
and FGFR2 in the presence of FGF2. In MPCs from 
3-month-old animals, we have documented that FGF2 
signals to a greater extent via PKC rather than by the 
previously identified MEK1/2–ERK1/2 signalling. In an 
attempt to determine the contribution of an additional 
signalling in FGF2-driven proliferation, we have also 
documented an increase in proliferation in the presence 
of p38 inhibition. The primary finding of decreased 
FGF2-stimulated proliferation in MPCs from old animals 
could be explained by unmeasured components of the 
measured signalling pathways or potential cross-talk 
between pathways that may be influenced via speculated 
antioxidant effects of DMSO. 
In future experiments, it will be necessary  to 
determine the specific pathway(s) that account for the 
ageing phenotype in FGF2-stimulated proliferation, the 
intracellular signalling pathways controlled by FGF2 and 
the potentially different roles for the various isoforms 
of PKC and p38. These findings will facilitate the 
development of treatment strategies aimed at improving 
age-related deficiencies in skeletal muscle repair and 
sarcopenia. 
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